We develop therapies that have potential as single agents and in combination to directly target underlying mechanisms driving cancer survival and growth. Our approach enables us to evolve and follow a path guided by translational approaches. See our unique process below.
A Multifaceted Approach
We are advancing a diverse array of therapies targeting cancer’s underlying drivers through clinical development.
- Ikena has a worldwide exclusive license except China and Taiwan from AskAt.
- Pembrolizumab provided through a clinical trial collaboration and supply agreement with Merck.
- BMS has the right to exclusively license under a master collaboration agreement.
- Nivolumab provided through a clinical trial collaboration and supply agreement with BMS.
We are ever-evolving
Visit our site in the near future for a deeper look at our team, our approach and our pipeline of oncology therapies.
At Ikena, we strive to see, know, and understand what drives every patient’s cancer so we can make an impact at its root. Every member of our team has something important to contribute to this goal.
Board of Directors
Scientific Advisory Board
Do you envision a world in which every cancer patient has a cure?
If you’re passionate about advancing cutting edge therapies for cancer patients, join our team.